Maybe they do intend to go alone on M-118? Or at least posture that way for negotiations.
I seriously doubt that for the reason you cited: cost.
What is the estimate on how much it would cost to run a phase 2b and phase 3 on M-118?
The short answer is: too much for MNTA to afford on its own, assuming that the point of the trial is to measure adverse clinical outcomes over a meaningful period of time for patients randomized to M118 or an active control regimen.
Thanks to the wonders of modern medicine, ACS trials that seek to show superiority or non-inferiority in clinical outcomes have to be very large because the overwhelming majority of patients in all trial arms will do OK.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.